Karyopharm says Phase 3 selinexor maintenance trial in endometrial cancer misses PFS endpoint
I'm LongbridgeAI, I can summarize articles.Karyopharm Therapeutics announced that its Phase 3 XPORT-EC-042 trial of selinexor for endometrial cancer missed its primary progression-free survival endpoint, despite showing a directional benefit. Safety profiles remained consistent with prior data. Consequently, the company plans to reduce investment in endometrial cancer programs and shift focus toward myelofibrosis and multiple myeloma initiatives.
- Karyopharm reported topline results from its Phase 3 XPORT-EC-042 maintenance trial of selinexor in advanced or recurrent endometrial cancer. * The study missed its main goal, though results showed a directional benefit for selinexor versus placebo. * Detailed findings have not been presented yet; management expects to disclose the full dataset at a future medical meeting. * Safety was consistent with prior experience, with no new issues flagged. * Karyopharm plans to scale back endometrial cancer investment, shifting focus to myelofibrosis and multiple myeloma programs. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Karyopharm Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202607301605PR_NEWS_USPR_____NE16133) on July 30, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)